CN112089883A - 一种医用冷敷敷料及其制备方法 - Google Patents
一种医用冷敷敷料及其制备方法 Download PDFInfo
- Publication number
- CN112089883A CN112089883A CN202010962984.7A CN202010962984A CN112089883A CN 112089883 A CN112089883 A CN 112089883A CN 202010962984 A CN202010962984 A CN 202010962984A CN 112089883 A CN112089883 A CN 112089883A
- Authority
- CN
- China
- Prior art keywords
- cold compress
- extract
- medical cold
- compress dressing
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 239000000017 hydrogel Substances 0.000 claims abstract description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000007788 liquid Substances 0.000 claims abstract description 37
- 238000002156 mixing Methods 0.000 claims abstract description 31
- 150000004676 glycans Chemical class 0.000 claims abstract description 28
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 28
- 239000005017 polysaccharide Substances 0.000 claims abstract description 28
- 235000013761 grape skin extract Nutrition 0.000 claims abstract description 24
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 21
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 20
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940041616 menthol Drugs 0.000 claims abstract description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 19
- 108010022355 Fibroins Proteins 0.000 claims abstract description 19
- 108010013296 Sericins Proteins 0.000 claims abstract description 19
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 19
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 19
- 239000003102 growth factor Substances 0.000 claims abstract description 17
- 238000005303 weighing Methods 0.000 claims abstract description 13
- 238000007789 sealing Methods 0.000 claims abstract description 12
- 230000001954 sterilising effect Effects 0.000 claims abstract description 12
- 238000007710 freezing Methods 0.000 claims abstract description 11
- 230000008014 freezing Effects 0.000 claims abstract description 11
- 238000001816 cooling Methods 0.000 claims abstract description 8
- 239000000499 gel Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 37
- 238000010438 heat treatment Methods 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 25
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 16
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 16
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 16
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 7
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 7
- 229940116977 epidermal growth factor Drugs 0.000 claims description 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 7
- 238000002137 ultrasound extraction Methods 0.000 claims description 6
- 241001474374 Blennius Species 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 241000011500 Phyllostachys praecox Species 0.000 claims description 4
- 235000008545 Phyllostachys praecox Nutrition 0.000 claims description 4
- 238000005360 mashing Methods 0.000 claims description 4
- 241000227647 Fucus vesiculosus Species 0.000 claims description 3
- 241000219095 Vitis Species 0.000 claims description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 241001495180 Arthrospira Species 0.000 claims description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 2
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 241000195634 Dunaliella Species 0.000 claims description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 2
- 241001491708 Macrocystis Species 0.000 claims description 2
- 244000082204 Phyllostachys viridis Species 0.000 claims description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 2
- 239000011425 bamboo Substances 0.000 claims description 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241000512260 Ascophyllum Species 0.000 claims 1
- 241000195493 Cryptophyta Species 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- MSXHSNHNTORCAW-MPGIDXPLSA-M sodium;(3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@@H]1OC(C([O-])=O)[C@@H](O)[C@H](O)[C@@H]1O MSXHSNHNTORCAW-MPGIDXPLSA-M 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 11
- 206010052428 Wound Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 230000008591 skin barrier function Effects 0.000 abstract description 8
- 230000003467 diminishing effect Effects 0.000 abstract description 7
- 230000008961 swelling Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000029663 wound healing Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 241000894006 Bacteria Species 0.000 abstract description 4
- 230000035699 permeability Effects 0.000 abstract description 4
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 230000003020 moisturizing effect Effects 0.000 abstract description 3
- 230000000474 nursing effect Effects 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 241000745988 Phyllostachys Species 0.000 abstract 1
- 238000000465 moulding Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 230000003385 bacteriostatic effect Effects 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 210000001339 epidermal cell Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 244000302661 Phyllostachys pubescens Species 0.000 description 5
- 235000003570 Phyllostachys pubescens Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241001491705 Macrocystis pyrifera Species 0.000 description 3
- 208000028990 Skin injury Diseases 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 240000003421 Dianthus chinensis Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 241000143459 Hirsutella Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000005827 Phyllostachys nigra Species 0.000 description 1
- 235000010717 Phyllostachys nigra Nutrition 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0261—Compresses or poultices for effecting heating or cooling medicated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种医用冷敷敷料及其制备方法。所述医用冷敷敷料包括如下组分:海藻多糖、亲水凝胶骨架材料、生长因子、透明质酸、丝胶蛋白、丝素蛋白、葡萄皮提取物、丝石竹提取物、舞草提取物、薄荷醇、水。所述冷敷敷料的制备方法为按质量称取上述组分,将其在一定条件下混合,得到一种水凝胶状液体。将水凝胶状液体脱泡后倒入模具,冷冻成型,得到水凝胶膜,将水凝胶膜真空密封后灭菌,得到本发明一种医用冷敷敷料。本发明提供的医用冷敷敷料能够作用于皮肤屏障的降温、修复护理,促进创面愈合,保护创面,具有补水、抗菌、消炎、消肿、抗氧化的功效,同时具有良好的成膜性、透气性、保湿性、生物相容性、皮肤贴合性。
Description
技术领域
本发明涉及医疗卫生技术领域中的医用敷料的生产技术领域,特别涉及一种医用冷敷敷料及其制备方法。
背景技术
皮肤是人体抵御外界伤害的重要屏障。在日常生活中,皮肤损伤极为常见,如皮肤擦伤、挫伤、轻微割伤、轻微烫伤烧伤、晒伤、轻度医美术后等意外或疾病引起的皮肤局部的浅表创面伤害,皮肤屏障损伤后,抵御能力下降,容易感染外界细菌,引起炎症反应如瘙痒、红肿、刺痛等部分的皮肤屏障受损时会伴随少量出血和组织液渗出等现象。因此,通常将医用敷料作用于皮肤屏障的修复护理,可起到保护创面、防止感染、修复、促进创面愈合等重要作用。
传统的医用敷料是由天然植物纤维或动物毛类物质构成,如纱布、羊毛、棉垫、油纱布等,具有较好的吸水性、保持创面的干燥、保护创面、成本低、原料来源广泛、质地柔软、使用简单等优点;但这类敷料存在不防水、易污染、易脱落、透气性差、无法保持创面湿润、不能促进创面愈合等缺点。
发明内容
本发明的目的在于提供一种医用冷敷敷料及其制备方法,该医用冷敷敷料能够作用于皮肤屏障的降温、修复护理,促进创面愈合,保护创面,具有补水、抗菌、消炎、消肿、抗氧化的功效,同时还具有良好的成膜性、透气性、保湿性、生物相容性、皮肤贴合性。
本发明采取的技术方案如下:
一种医用冷敷敷料,由以下组份组成:按质量百分比计,海藻多糖10-15%、亲水凝胶骨架材料3-5%、生长因子0.002-0.003%、透明质酸3-7%、丝胶蛋白3-5%、丝素蛋白5-8%、葡萄皮提取物1-3%、丝石竹提取物4-6%、舞草提取物3-5%、薄荷醇0.5-1%、余量是水。
优选的,生长因子为表皮细胞生长因子类或成纤维细胞生长因子类的一种。
优选的,亲水凝胶骨架材料为羟甲基纤维素、羧甲基纤维素钠、脱乙酰壳多糖中的一种或多种。
优选的,海藻多糖为海藻洗涤后粉碎,于5000-10000rpm离心1-3分钟,去上清,向沉淀物中依次加入纤维素酶、木瓜蛋白酶进行酶解,加热至100-110℃保温5-10min灭酶后,于70-90℃加热浸提1-3h,冷却后过滤浓缩,浓缩液经乙醇沉淀法处理所得。
优选的,海藻为鸭毛藻、松节藻、巨藻、泡叶藻、墨角藻中的一种或多种。
优选的,葡萄皮提取物为将葡萄皮清洗后加水,进行超声波提取,超声波功率为280-360W,提取时间为20-30min,过滤,浓缩滤液后所得。
优选的,丝石竹提取物为将丝石竹的根、茎研磨成粉,加入乙醇水溶液,进行超声波提取,超声波功率为300-400W,提取时间为为20-30min,过滤,向滤液中依次用石油醚、乙醚萃取,去除有机溶剂层,于50-60℃加热10-15min后,1000-2000rpm离心3-5分钟,得上清液,浓缩上清液所得。
优选的,舞草提取物为为将舞草的叶片捣烂,加入乙醇于55-65℃加热浸提15-30min,静置冷却后,过滤,浓缩滤液干燥所得。
一种医用冷敷敷料的制备方法,包括以下步骤:
S1、按比例称取各组分原料,将亲水凝胶骨架材料和水混合后加热至90-95℃搅拌溶解,于40-50℃加入海藻多糖、透明质酸、葡萄皮提取物、丝石竹提取物、舞草提取物,搅拌溶解后得到溶液A;
S2、将生长因子、丝胶蛋白、丝素蛋白和水混合后,得到溶液B;
S3、将溶液A加热至55-65℃时,加入溶液B,搅拌均匀后加入薄荷醇,混合均匀后,得到一种水凝胶状液体;
S4、将步骤S3中的水凝胶状液体脱泡后,倒入成型模具中,置于-25~-20℃冷冻8-12h,得到成型的水凝胶膜;
S5、将步骤S4中成型的水凝胶膜真空密封后灭菌,得医用冷敷敷料。
本发明与现有技术相比具有如下有益效果:
1、本发明的医用冷敷敷料中添加海藻多糖、葡萄皮提取物、舞草提取物具有补水、抗菌、消炎、抗氧化等作用,能够对皮肤屏障进行防护和修复;丝石竹提取物和薄荷醇能够使消肿皮肤、降温皮肤屏障、缓解皮肤红肿发热症状;海藻多糖、亲水凝胶骨架材料的协同作用使医用冷敷敷料具有良好的成膜性、透气性、保湿性、生物相容性、皮肤亲和性。
2、本发明的医用冷敷敷料为固体水凝胶状,具有良好的吸水性、锁水性、柔软性和粘弹性,能够完美贴服在皮肤表面,维持湿性愈合条件,敷料中添加透明质酸、生长因子、丝胶蛋白、丝素蛋白具有协同作用,生长因子能够快速进入皮肤、促进皮肤吸收养分,透明质酸、丝胶蛋白、丝素蛋白能够为皮肤补充养分,促进伤口愈合,修复皮肤屏障。
3、本发明添加海藻多糖、葡萄皮提取物、舞草提取物具有抑菌作用,不额外添加防腐剂,在保证抑菌效果的同时不会对皮肤及创口产生刺激,安全无毒害。
4、本发明医用冷敷敷料的制备工艺简单,操作方便,可大规模工业化生产。
具体实施方式
为了更好理解本发明技术内容,下面提供具体实施例,对本发明做进一步的说明。
实施例1
一种医用冷敷敷料,所述医用冷敷敷料由以下组份组成:按质量百分比计,海藻多糖15%、羧甲基纤维素钠5%、表皮细胞生长因子0.002%、透明质酸7%、丝胶蛋白5%、丝素蛋白8%、葡萄皮提取物3%、丝石竹提取物6%、舞草提取物5%、薄荷醇0.5%、余量是水。
所述海藻多糖为巨藻洗涤后,于5000rpm,离心3分钟,去上清,向沉淀物中依次加入纤维素酶、木瓜蛋白酶进行酶解,加热至100℃保温10min灭酶后,于90℃加热浸提1h,冷却后过滤浓缩,浓缩液经乙醇沉淀法处理所得。
所述葡萄皮提取物为将葡萄皮清洗后加水,进行超声波提取,超声波功率为360W,提取时间为20min,过滤,浓缩滤液所得。
所述丝石竹提取物为将丝石竹的根、茎研磨成粉,加入乙醇水溶液,进行超声波提取,超声波功率为300W,提取时间为为30min,过滤,向滤液中依次用石油醚、乙醚萃取,去除有机溶剂层,于60℃加热15min后,2000rpm离心5分钟,得上清液,浓缩上清液所得。
所述舞草提取物为为将舞草的叶片捣烂,加入乙醇于65℃加热浸提15min,静置冷却后,过滤,浓缩滤液后干燥所得。
一种医用冷敷敷料的制备方法,包括以下步骤:
S1、按比例称取各组分原料,将羧甲基纤维素钠和水混合后加热至90℃搅拌溶解,于50℃加入海藻多糖、透明质酸、丝石竹提取物、舞草提取物、葡萄皮提取物,搅拌溶解后得到溶液A;
S2、将表皮细胞生长因子、丝胶蛋白、丝素蛋白和水混合后,得到溶液B;
S3、将溶液A加热至65℃时,加入溶液B,搅拌均匀后加入薄荷醇,混合均匀后,得到一种水凝胶状液体;
S4、将步骤S3中的水凝胶状液体脱泡后,倒入成型模具中,置于-20℃冷冻12h,得到成型的水凝胶膜;
S5、将步骤S4中成型的水凝胶膜真空密封后灭菌,得一种医用冷敷敷料。
实施例2
实施例2与实施例1的区别在于:
所述海藻多糖为将巨藻粉碎,加水于60℃水浴提取8h,浸提3次,提取液浓缩,加入乙醇,在冰箱中静置12h后离心,收集沉淀,冷冻干燥所得。
实施例3
实施例3与实施例1的区别在于:
所述海藻多糖为松节藻、泡叶藻和墨角藻混合洗涤后粉碎,于8000pm离心3分钟,去上清,向沉淀物中依次加入纤维素酶、木瓜蛋白酶进行酶解,加热至100℃保温10min灭酶后,于80℃加热浸提2h,冷却后过滤浓缩,浓缩液经乙醇沉淀法处理所得。
所述葡萄皮提取物为市售含有原花青素、多酚的葡萄皮提取物。
实施例4
实施例4与实施例1的区别在于:
所述海藻多糖为鸭毛藻和巨藻混合洗涤后粉碎,于5000-10000rpm离心1-3分钟,去上清,向沉淀物中依次加入纤维素酶、木瓜蛋白酶进行酶解,加热至110℃保温5min灭酶后,于70℃加热浸提3h,冷却后过滤浓缩,浓缩液经乙醇沉淀法处理所得。
所述丝石竹提取物为市售含有黄酮甙、酚类、氨基酸、挥发油、香豆素的丝石竹提取物。
实施例5
实施例5与实施例1的区别在于:
所述舞草提取物为将舞草的根茎捣烂,加水,于60℃加热浸提6h,趁热过滤,浓缩滤液所得。
实施例6
实施例6与实施例1的不同在于:
一种医用冷敷敷料的制备方法,包括以下步骤:
S1、按比例称取各组分原料,将羧甲基纤维素钠和水混合后加热至90℃搅拌溶解,于50℃加入海藻多糖、透明质酸、丝石竹提取物、舞草提取物、葡萄皮提取物、表皮细胞生长因子、丝胶蛋白、丝素蛋白,搅拌溶解后,加入薄荷醇,混合均匀后,得到一种水凝胶状液体;
S2、将步骤S1中的水凝胶状液体脱泡后,倒入成型模具中,置于-20℃冷冻12h,得到成型的水凝胶膜;
S3、将步骤S2中成型的水凝胶膜真空密封后灭菌,得一种医用冷敷敷料。
实施例7
实施例7与实施例1的不同在于:
一种医用冷敷敷料的制备方法,包括以下步骤:
S1、按比例称取各组分原料,将羧甲基纤维素钠和水混合后加热至90℃搅拌溶解,于50℃加入表皮细胞生长因子、丝胶蛋白、丝素蛋白,搅拌溶解后得到溶液A;
S2、将海藻多糖、透明质酸、丝石竹提取物、舞草提取物、葡萄皮提取物和水混合后,得到溶液B;
S3、将溶液A加热至65℃时,加入溶液B,搅拌均匀后加入薄荷醇,混合均匀后,得到一种水凝胶状液体;
S4、将步骤S3中的水凝胶状液体脱泡后,倒入成型模具中,置于-20℃冷冻12h,得到成型的水凝胶膜;
S5、将步骤S4中成型的水凝胶膜真空密封后灭菌,得一种医用冷敷敷料。
实施例8
实施例8与实施例1的区别在于:
一种医用冷敷敷料的制备方法,包括以下步骤:
S1、按比例称取各组分原料,将羧甲基纤维素钠和水混合后加热至80℃搅拌溶解,于60℃加入海藻多糖、透明质酸、丝石竹提取物、舞草提取物、葡萄皮提取物,搅拌溶解后得到溶液A;
S2、将表皮细胞生长因子、丝胶蛋白、丝素蛋白和水混合后,得到溶液B;
S3、将溶液A加热至50℃时,加入溶液B,搅拌均匀后加入薄荷醇,混合均匀后,得到一种水凝胶状液体;
S4、将步骤S3中的水凝胶状液体脱泡后,倒入成型模具中,置于-10℃冷冻12h,得到成型的水凝胶膜;
S5、将步骤S4中成型的水凝胶膜真空密封后灭菌,得一种医用冷敷敷料。
对比例1
对比例1与实施例1的区别在于:
所述医用冷敷敷料由以下组份组成:按质量百分比计,海藻多糖17%、羧甲基纤维素钠5%、表皮细胞生长因子0.002%、透明质酸7%、丝胶蛋白5%、丝素蛋白8%、葡萄皮提取物4%、丝石竹提取物7%、舞草提取物6%、薄荷醇0.5%、余量是水。
对比例2
对比例2与实施例1的区别在于:
所述医用冷敷敷料由以下组份组成:按质量百分比计,羧甲基纤维素钠5%、表皮细胞生长因子0.002%、透明质酸7%、丝胶蛋白5%、丝素蛋白8%、丝石竹提取物6%、薄荷醇0.5%、维生素E 2%、甘草精原液3%、余量是水。
一种医用冷敷敷料的制备方法,包括以下步骤:
S1、按比例称取各组分原料,将羧甲基纤维素钠和水混合后加热至80℃搅拌溶解,于45℃加入维生素E、透明质酸、甘草精原液,搅拌溶解后得到溶液A;
S2、将表皮细胞生长因子、丝胶蛋白、丝素蛋白和水混合后,得到溶液B;
S3、将溶液A加热至50℃时,加入溶液B,搅拌均匀后加入薄荷醇,混合均匀后,得到一种水凝胶状液体;
S4、将步骤S3中的水凝胶状液体脱泡后,倒入成型模具中,置于-10℃冷冻12h,得到成型的水凝胶膜;
S5、将步骤S4中成型的水凝胶膜真空密封后灭菌,得一种医用冷敷敷料。
对比例3
对比例3与实施例1的区别在于:
所述医用冷敷敷料由以下组份组成:按质量百分比计,海藻多糖15%、表皮细胞生长因子0.002%、透明质酸7%、丝胶蛋白5%、丝素蛋白8%、葡萄皮提取物3%、丝石竹提取物6%、舞草提取物5%、薄荷醇0.5%、余量是水。
一种医用冷敷敷料的制备方法,包括以下步骤:
S1、按比例称取各组分原料,将水加热至60℃加入海藻多糖、透明质酸、葡萄皮提取物、丝石竹提取物、舞草提取物,搅拌溶解后得到溶液A;
S2、将生长因子、丝胶蛋白、丝素蛋白和水混合后,得到溶液B;
S3、将溶液A加热至70℃时,加入溶液B,搅拌均匀后加入薄荷醇,混合均匀后,得到一种液体敷料;
S4、将步骤S3中的液体敷料,倒入包装袋中,加入无纺布;
S5、将步骤S4中包装袋真空密封后灭菌,得一种医用冷敷敷料。
对比例4
对比例4与实施例1的区别在于:
所述医用冷敷敷料由以下组份组成:按质量百分比计,羧甲基纤维素钠5%、薄荷醇0.5%、余量是水。
一种医用冷敷敷料的制备方法,包括以下步骤:
S1、按比例称取各组分原料,将羧甲基纤维素钠和水混合后加热至90℃搅拌溶解,于65℃加入薄荷醇,混合均匀后,得到一种水凝胶状液体;
S2、将步骤S1中的水凝胶状液体脱泡后,倒入成型模具中,置于-20℃冷冻12h,得到成型的水凝胶膜;
S3、将步骤S2中成型的水凝胶膜真空密封后灭菌,得一种医用冷敷敷料。
对比例5
对比例5与实施例1的区别在于:
所述医用冷敷敷料由以下组份组成:按质量百分比计,羧甲基纤维素钠5%、表皮细胞生长因子0.002%、透明质酸7%、丝胶蛋白5%、丝素蛋白8%、余量是水。
一种医用冷敷敷料的制备方法,包括以下步骤:
S1、按比例称取各组分原料,将羧甲基纤维素钠和水混合后加热至90℃搅拌溶解后得到溶液A;
S2、将透明质酸、表皮细胞生长因子、丝胶蛋白、丝素蛋白和水混合后,得到溶液B;
S3、待溶液A温度为65℃时,加入溶液B,混合均匀后,得到一种水凝胶状液体;
S4、将步骤S3中的水凝胶状液体脱泡后,倒入成型模具中,置于-20℃冷冻12h,得到成型的水凝胶膜;
S5、将步骤S4中成型的水凝胶膜真空密封后灭菌,得一种医用冷敷敷料。
对比例6
对比例6与实施例1的区别在于:
所述医用冷敷敷料由以下组份组成:按质量百分比计,羧甲基纤维素钠5%、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐0.1-0.5%、余量是水。
一种医用冷敷敷料的制备方法,包括以下步骤:
S1、按比例称取各组分原料,将羧甲基纤维素钠、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐和水混合后加热至90℃搅拌均匀,得到一种水凝胶状液体;
S2、将步骤S1中的水凝胶状液体脱泡后,倒入成型模具中,置于-20℃冷冻12h,得到成型的水凝胶膜;
S3、将步骤S2中成型的水凝胶膜真空密封后灭菌,得到一种医用冷敷敷料。
试验例1持水性能测试
取本发明实施例与对比例制备得到的医用冷敷敷料,对其持水性能进行测试,将上述敷料裁剪为1cm*1cm大小后,放在洁净的玻璃瓶中称重,然后真空干燥,保持37℃,30个大气压,干燥3天。脱水干燥后的敷料分别称重,每个样品测3组,取平均值。将上述真空干燥的敷料,浸入与人体液盐含量相同的0.9wt%的生理盐水溶液中,将生理盐水溶液的温度保持在37℃。每隔3h,用滤纸将溶胀的水凝胶的表面的水分拭干,直到敷料达到最大的含水量后,分别称重取平均值。测试结果如下表1所示。
含水量=(Ww-Wo)/Ww
Ww为干燥前的敷料质量,Wo为干燥后的敷料质量
吸水率的计算式:Qs=(Ws-Wo)/Wo×100%
Ws为溶胀的敷料质量
表1持水性能测试结果
组别 | 含水量(%)≥ | 吸水率(%)≥ |
实施例1 | 93 | 476 |
实施例2 | 85 | 432 |
实施例3 | 94 | 475 |
实施例4 | 95 | 473 |
实施例5 | 93 | 478 |
实施例6 | 82 | 417 |
实施例7 | 76 | 395 |
实施例8 | 78 | 386 |
对比例1 | 63 | 258 |
对比例2 | 54 | 235 |
对比例3 | 51 | 198 |
对比例4 | 42 | 208 |
对比例5 | 46 | 216 |
对比例6 | 48 | 327 |
由实验数据可知,本发明的医用冷敷敷料具有较好的持水性能,能够维持贴敷部位的湿润环境加速伤口的愈合。
其中,实施例1-8与对比例3,表明水凝胶敷料的持水性能比液体敷料好,
实施例1-5与对比例1-2,表明海藻多糖具有良好的持水性能,且表明本发明的海藻多糖具有较好的持水性能。
实施例1-8,表明采用本发明制备方法制得的医用冷敷敷料的持水性较好。
实施例1-5与对比例4-6,表明采用本发明医用冷敷敷料组成成分制得水凝胶敷料的持水性能比一般水凝胶敷料好。
试验例2产品疗效试验
取本发明实施例与对比例制备得到的医用冷敷敷料,对其进行产品疗效试验,试验方法如下:
受试者选择:选择年龄在18-65岁(含边界值)间,皮肤受损面积为30%-60%的受试者140例,男女各一半;每组病人10例。
实施方法:在使用医用冷敷敷料前,先将伤患部位洗干净,然后将敷料贴敷在伤患部位,贴敷15-25min,每天使用一次敷料,7天为一个疗程;疗程期内受试者伤患部位不使用其他产品,分别于疗程开始的第1天,第3天,第5天,第7天,记录病人伤患部位皮肤受损症状消退情况。
皮肤受损表现为:面部皮肤局部红肿、发热、轻度瘙痒、轻微刺痛等损伤。
疗效判断标准:伤患部位皮肤受损症状完全消失为治愈。
表2医用冷敷敷料治愈率统计表
组别 | 1天 | 3天 | 5天 | 7天 |
实施例1 | 20% | 70% | 100% | 100% |
实施例2 | 10% | 60% | 90% | 100% |
实施例3 | 10% | 50% | 80% | 90% |
实施例4 | 10% | 50% | 80% | 90% |
实施例5 | 10% | 50% | 70% | 90% |
实施例6 | 0% | 50% | 70% | 80% |
实施例7 | 0% | 40% | 60% | 80% |
实施例8 | 0% | 40% | 60% | 80% |
对比例1 | 0% | 20% | 40% | 60% |
对比例2 | 0% | 10% | 30% | 50% |
对比例3 | 0% | 30% | 50% | 60% |
对比例4 | 0% | 0% | 20% | 30% |
对比例5 | 0% | 0% | 20% | 30% |
对比例6 | 0% | 0% | 10% | 30% |
由实验数据可知,本发明的医用冷敷敷料对治疗皮肤受损症状在第3天的治愈率就可达到40%,最快5天治愈率就能达到100%,说明本发明具有一定的降温、镇痛、消炎、消肿的作用,还可以对皮肤进行修复。
其中,实施例1-2与对比例1-2,表明本发明的海藻多糖具有较好疗效效果。
实施例1、3、4、5与对比例1,表明葡萄皮提取物、丝石竹提取物、舞草提取物具有一定的疗效效果。
实施例1-8,表明采用本发明制备方法制得的医用冷敷敷料的疗效效果好。
实施例1与对比例3,表明本发明制得的水凝胶敷料比液体敷料的效果好。
实施例1-5与对比例4,表明本发明添加了薄荷醇的水凝胶敷料比添加薄荷醇的常规水凝胶敷料的疗效效果好。
实施例1-5与对比例5,表明本发明医用冷敷敷料的疗效效果比常规添加了透明质酸、生长因子、丝胶蛋白、丝素蛋白的水凝胶敷料好。
实施例1-5与对比例6,表明本发明的水凝胶敷料的疗效效果比常规水凝胶敷料好。
试验例3抑菌圈试验
使用大肠杆菌、金黄色葡萄球菌和白色念珠菌进行抑菌圈试验,将供试菌(浓度约为105cfu/mL)取0.001mL置于离心管中,稀释浓度为107cfu/mL。使用涂布法,于灭菌后冷却凝固的琼脂培养基表面分别涂布稀释过的细菌悬液。向培养基中放入大小一致的敷料样品,每个培养基放三个样品,作为平行组。最后,将培养基置于恒温培养箱中,于37℃下培养24h后测量抑菌圈大小,结果如表3所示。
表3抑菌圈试验结果
由实验数据可知,实施例的抑菌圈均明显大于对比例,说明本发明医用冷敷敷料具有良好的抑菌效果。
其中,实施例1-5与对比例1-2,表明本发明技术方案中添加的海藻多糖、葡萄皮提取物、舞草提取物的抑菌效果较好,实施例2-5未采用本发明的海藻多糖、葡萄皮提取物、舞草提取物的效果较实施例1差,对比例2未添加海藻多糖、葡萄皮提取物、舞草提取物的抑菌效果最差。
实施例1-8,表明采用本发明制备方法制得的医用冷敷敷料,能够最大程度的保留有效成分的抑菌效果。
实施例1-5与对比例4-6,表明本发明的医用冷敷敷料的抑菌效果好。
本发明的一种医用冷敷敷料适用范围:轻中度炎症、较轻痤疮、痤疮的治疗;皮肤过敏、激光、光子治疗术后皮肤的发红发烫的治疗;在创面愈合期促进创面的愈合等。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种医用冷敷敷料,其特征在于,所述医用冷敷敷料由以下组份组成:按质量百分比计,海藻多糖10-15%、亲水凝胶骨架材料3-5%、生长因子0.002-0.003%、透明质酸3-7%、丝胶蛋白3-5%、丝素蛋白5-8%、葡萄皮提取物1-3%、丝石竹提取物4-6%、舞草提取物3-5%、薄荷醇0.5-1%、余量是水。
2.根据权利要求1所述医用冷敷敷料,其特征在于,所述生长因子为表皮细胞生长因子类或成纤维细胞生长因子类的一种。
3.根据权利要求1所述医用冷敷敷料,其特征在于,所述亲水凝胶骨架材料为羟甲基纤维素、羧甲基纤维素钠、脱乙酰壳多糖中的一种或多种。
4.根据权利要求1所述医用冷敷敷料,其特征在于,所述海藻多糖为海藻洗涤后粉碎,于5000-10000rpm离心1-3分钟,去上清,向沉淀物中依次加入纤维素酶、木瓜蛋白酶进行酶解,加热至100-110℃保温5-10min灭酶后,于70-90℃加热浸提1-3h,冷却过滤浓缩,浓缩液经乙醇沉淀法处理所得。
5.根据权利要求4中所述医用冷敷敷料,其特征在于,所述海藻为鸭毛藻、松节藻、巨藻、泡叶藻、墨角藻中的一种或多种。
6.根据权利要求1所述医用冷敷敷料,其特征在于,所述葡萄皮提取物为将葡萄皮清洗后加水,进行超声波提取,超声波功率为280-360W,提取时间为20-30min,过滤后,浓缩滤液所得。
7.根据权利要求1所述医用冷敷敷料,其特征在于,所述丝石竹提取物为将丝石竹的根、茎研磨成粉,加入乙醇水溶液,进行超声波提取,超声波功率为300-400W,提取时间为为20-30min,过滤,向滤液中依次用石油醚、乙醚萃取,去除有机溶剂层,于50-60℃加热10-15min后,1000-2000rpm离心3-5分钟,得上清液,浓缩上清液所得。
8.根据权利要求1所述医用冷敷敷料,其特征在于,所述舞草提取物为将舞草的叶片捣烂,加入乙醇,于55-65℃加热浸提15-30min,静置冷却后,过滤,浓缩滤液后干燥所得。
9.根据权利要求1-8中任一项所述的医用冷敷敷料的制备方法,其特征在于,包括以下步骤:
S1、按比例称取各组分原料,将亲水凝胶骨架材料和水混合后加热至90-95℃搅拌溶解,于40-50℃加入海藻多糖、透明质酸、葡萄皮提取物、丝石竹提取物、舞草提取物,搅拌溶解后得到溶液A;
S2、将生长因子、丝胶蛋白、丝素蛋白和水混合后,得到溶液B;
S3、将溶液A加热至55-65℃时,加入溶液B,搅拌均匀后加入薄荷醇,混合均匀后,得到一种水凝胶状液体;
S4、将步骤S3中的水凝胶状液体脱泡后,倒入成型模具中,置于-25~-20℃冷冻8-12h,得到成型的水凝胶膜;
S5、将步骤S4中成型的水凝胶膜真空密封后灭菌,得医用冷敷敷料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010962984.7A CN112089883B (zh) | 2020-09-14 | 2020-09-14 | 一种医用冷敷敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010962984.7A CN112089883B (zh) | 2020-09-14 | 2020-09-14 | 一种医用冷敷敷料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112089883A true CN112089883A (zh) | 2020-12-18 |
CN112089883B CN112089883B (zh) | 2022-01-04 |
Family
ID=73752440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010962984.7A Active CN112089883B (zh) | 2020-09-14 | 2020-09-14 | 一种医用冷敷敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112089883B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112535760A (zh) * | 2020-12-28 | 2021-03-23 | 广州麦嘉昕生物科技有限公司 | 一种修复型医用冷敷敷料 |
CN112656989A (zh) * | 2020-12-28 | 2021-04-16 | 广州麦嘉昕生物科技有限公司 | 一种温阳型医用冷敷敷料 |
CN114081711A (zh) * | 2021-11-16 | 2022-02-25 | 江苏凯顺医疗器械有限公司 | 一种三元复合医用冷热敷料及其制备方法 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1378255A2 (en) * | 2002-06-28 | 2004-01-07 | Ethicon, Inc. | Hemostatic wound dressing and method of making same |
AU2005262070A1 (en) * | 2004-07-09 | 2006-01-19 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
WO2010005480A2 (en) * | 2008-06-16 | 2010-01-14 | Biovascular, Inc. | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
CN101816802A (zh) * | 2010-02-05 | 2010-09-01 | 佘振定 | 一种壳聚糖基医用敷料 |
US20120134967A1 (en) * | 2005-12-13 | 2012-05-31 | Mooney David J | Scaffolds For Cell Transplantation |
WO2013064831A1 (en) * | 2011-11-01 | 2013-05-10 | Brightwake Limited | Wound dressings, and yarn useful therein |
EP2668943A1 (en) * | 2012-05-31 | 2013-12-04 | Confluent Surgical, Inc. | Microspheres including oxidized cellulose |
CN103463668A (zh) * | 2013-09-05 | 2013-12-25 | 浙江大学 | 一种丝素-海藻酸钙生物创面多孔敷料的制备方法 |
CN104548200A (zh) * | 2015-02-06 | 2015-04-29 | 武汉纺织大学 | 一种制备高支化多糖-丝素水凝胶支架的方法 |
CN105816911A (zh) * | 2016-05-31 | 2016-08-03 | 武汉兵兵药业有限公司 | 一种含生长因子的修复凝胶及其制备方法 |
US20170100427A1 (en) * | 2008-04-24 | 2017-04-13 | Medtronic, Inc. | Polysaccharide particle mixture |
CN111166931A (zh) * | 2020-01-21 | 2020-05-19 | 海南卓瑞生物医药有限公司 | 一种甲基丙烯酸丝胶/壳聚糖季铵盐水凝胶及其制备方法和应用 |
-
2020
- 2020-09-14 CN CN202010962984.7A patent/CN112089883B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1378255A2 (en) * | 2002-06-28 | 2004-01-07 | Ethicon, Inc. | Hemostatic wound dressing and method of making same |
AU2005262070A1 (en) * | 2004-07-09 | 2006-01-19 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
US20120134967A1 (en) * | 2005-12-13 | 2012-05-31 | Mooney David J | Scaffolds For Cell Transplantation |
US20170100427A1 (en) * | 2008-04-24 | 2017-04-13 | Medtronic, Inc. | Polysaccharide particle mixture |
WO2010005480A2 (en) * | 2008-06-16 | 2010-01-14 | Biovascular, Inc. | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
CN101816802A (zh) * | 2010-02-05 | 2010-09-01 | 佘振定 | 一种壳聚糖基医用敷料 |
WO2013064831A1 (en) * | 2011-11-01 | 2013-05-10 | Brightwake Limited | Wound dressings, and yarn useful therein |
EP2668943A1 (en) * | 2012-05-31 | 2013-12-04 | Confluent Surgical, Inc. | Microspheres including oxidized cellulose |
CN103463668A (zh) * | 2013-09-05 | 2013-12-25 | 浙江大学 | 一种丝素-海藻酸钙生物创面多孔敷料的制备方法 |
CN104548200A (zh) * | 2015-02-06 | 2015-04-29 | 武汉纺织大学 | 一种制备高支化多糖-丝素水凝胶支架的方法 |
CN105816911A (zh) * | 2016-05-31 | 2016-08-03 | 武汉兵兵药业有限公司 | 一种含生长因子的修复凝胶及其制备方法 |
CN111166931A (zh) * | 2020-01-21 | 2020-05-19 | 海南卓瑞生物医药有限公司 | 一种甲基丙烯酸丝胶/壳聚糖季铵盐水凝胶及其制备方法和应用 |
Non-Patent Citations (4)
Title |
---|
周姝妤等: "胶原蛋白/纤维素纳米晶体敷料的制备及性能", 《功能高分子学报》 * |
姚康德等: "组织工程用生物降解材料特性", 《材料导报》 * |
李承明等: "明胶在创伤敷料中的应用", 《明胶科学与技术》 * |
蔡伟杰等: "水凝胶敷料治疗慢性创面研究进展", 《国际骨科学杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112535760A (zh) * | 2020-12-28 | 2021-03-23 | 广州麦嘉昕生物科技有限公司 | 一种修复型医用冷敷敷料 |
CN112656989A (zh) * | 2020-12-28 | 2021-04-16 | 广州麦嘉昕生物科技有限公司 | 一种温阳型医用冷敷敷料 |
CN114081711A (zh) * | 2021-11-16 | 2022-02-25 | 江苏凯顺医疗器械有限公司 | 一种三元复合医用冷热敷料及其制备方法 |
CN114081711B (zh) * | 2021-11-16 | 2024-05-28 | 万家济中医药科技(山东)有限公司 | 一种三元复合医用冷热敷料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112089883B (zh) | 2022-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112089883B (zh) | 一种医用冷敷敷料及其制备方法 | |
CN106822988B (zh) | 海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴 | |
CN111632075B (zh) | 一种促进皮肤创面愈合的外泌体制剂及其制备方法 | |
CN111388346A (zh) | 一种植物蛋白与多肽配方的冻干粉活面膜及其制备方法 | |
CN111616992B (zh) | 一种皮肤屏障修护复合物、肌底液及其制备方法 | |
CN110882207A (zh) | 一种用于皮肤修护的精华液制备工艺与方法 | |
CN110787100A (zh) | 抗敏舒肤精华液及其制备方法 | |
CN108042436B (zh) | 蓝铜胜肽抗衰保湿精华霜 | |
CN107714631B (zh) | 一种胶原蛋白肽面膜液及其制备方法 | |
CN111921005A (zh) | 一种含小蓟提取物的止血、抗菌敷料的制备方法 | |
CN109700998B (zh) | 一种复方肌肤损伤再生修复剂及其制备方法 | |
CN110934798A (zh) | 一种含有寡肽和向日葵干细胞的面膜及其制备方法 | |
CN109010178B (zh) | 一种沐浴露及其生产工艺 | |
CN108186426B (zh) | 一种抑菌面膜液、面膜及其制备方法 | |
CN111991612A (zh) | 一种具有镇痛、抗菌功能的液体敷料制备方法 | |
CN111012945A (zh) | 一种新型防水中药液体创可贴及其制备方法 | |
CN106668331A (zh) | 一种具有消炎抑菌及促进创面愈合的组合物及制配方法 | |
CN107789611B (zh) | 一种胶原蛋白肽润滑液及其制备方法 | |
CN112023110B (zh) | 一类基于竹荪蛋提取物的活性抑菌敷料 | |
CN114159341B (zh) | 一种冻干眼贴及其制备方法 | |
CN108403570A (zh) | 对湿疹引起的皮肤瘙痒有改善效果的体用凝露及制备方法 | |
CN107865817A (zh) | 一种含有蜗牛粘液与玻尿酸的消炎祛痘面膜液的制备方法 | |
CN112169008A (zh) | 一种基于人源胶原蛋白的医用敷料的制备方法 | |
KR102218008B1 (ko) | 알로에를 이용한 하이드로겔 마스크팩의 제조방법 및 이를 이용하여 제조된 하이드로겔 마스크팩 | |
CN113648336A (zh) | 一种基于蜂蜜与积雪草外泌体的制备提取方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |